Mammary Cell News Volume 9.26 | Jul 6 2017

TOP STORY

Cold Atmospheric Plasma Restores Tamoxifen Sensitivity in Resistant MCF-7 Breast Cancer Cell

Investigators developed a tamoxifen (Tam)-resistant MCF-7 breast cancer cell model and examined the effect of cold atmospheric plasma on the recovery of Tam sensitivity at the cellular and molecular level. [Free Radic Biol Med] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Downregulation of ATG5-Dependent Macroautophagy by Chaperone-Mediated Autophagy Promotes Breast Cancer Cell Metastasis

Researchers found that the lysosome-associated membrane protein type 2A (LAMP2A) protein level was significantly elevated in human breast cancer tissues, particularly in metastatic carcinoma. The increased LAMP2A level was also positively correlated with the histologic grade of ductal breast cancer. [Sci Rep] Full Article

Extracellular Matrix Promotes Clathrin-Dependent Endocytosis of Prolactin and STAT5 Activation in Differentiating Mammary Epithelial Cells

Scientists showed that clathrin-mediated endocytosis is required for extracellular matrix (ECM)-dependent STAT5 activation. In the presence of ECM, prolactin is internalized via a clathrin-dependent, but caveolin-independent, route. [Sci Rep] Full Article

Two Distinct mTORC2-Dependent Pathways Converge on Rac1 to Drive Breast Cancer Metastasis

Migration and invasion of human epidermal growth factor receptor 2-amplified human breast cancer cells was diminished in the absence of Rictor, or upon pharmacological mTOR kinase inhibition. Active Rac1 was required for Rictor-dependent invasion and motility, which rescued invasion/motility in Rictor depleted cells. [Breast Cancer Res] Full Article

TGFβ/NR4A1 Inducible Breast Cancer Cell Migration and Epithelial to Mesenchymal Transition is p38α (MAPK14) Dependent

Transforming growth factor β (TGFβ)/p38α and NR4A1 play essential roles in the induction of epithelial to mesenchymal transition and induction of β-catenin in triple negative breast cancer cells, and these TGFβ-induced responses and nuclear export of NR4A1 are blocked by NR4A1 antagonists, the p38 inhibitor SB202190, kinase dead and dominant negative forms of p38α. [Mol Cell Biol] Abstract

Glyceollins Trigger Anti-Proliferative Effects through Estradiol-Dependent and Independent Pathways in Breast Cancer Cells

The authors showed that synthetic versions of glyceollin I and II exert anti-proliferative effects in vivo in mouse mammary glands and in vitro in different estrogen receptor (ER)-positive and ER-negative breast cell lines. [Cell Commun Signal] Full Article

Morphology-Based Optical Separation of Subpopulations from a Heterogeneous Murine Breast Cancer Cell Line

Scientists used a morphology-based optical cell separation process to classify a heterogeneous cancer cell population into characteristic subpopulations. To classify the cell subpopulations, they assessed their morphology in hydrogel, a three-dimensional culture environment that induces morphological changes according to the characteristics of the cells. [PLoS One] Full Article

Depletion of Carbonic Anhydrase IX Abrogates Hypoxia-Induced Overexpression of Stanniocalcin-1 in Triple Negative Breast Cancer Cells

In order to gain an insight into the mechanism of action of carbonic anhydrase IX (CAIX) inhibitors, researchers investigated the impact of CAIX knock-down on the transcriptional response to hypoxia in two BC cell lines – MCF7 and MDA-MB-231, by performing a global gene expression analysis. [Cancer Biol Ther] Abstract

Celecoxib Induced Apoptosis against Different Breast Cancer Cell Lines by Down-Regulated NF-κB Pathway

The authors found that Celecoxib inhibited the proliferation of the MDA-MB-231 cell line in a dose-time dependent manner versus SK-BR-3 in a dose dependent manner only. Celecoxib induced apoptosis of the MDA-MB-231 and SK-BR-3 cell lines in a dose-time dependent manner with more mean apoptotic cells in MDA-MB-231 than SK-BR-3. [Biochem Biophys Res Commun] Abstract

CLINICAL RESEARCH

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

In this multicenter, open-label, Phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel and cyclophosphamide every three weeks or three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel. [J Clin Oncol] Full Article

First Report of Eribulin in Combination with Pertuzumab and Trastuzumab for Advanced HER2-Positive Breast Cancer

In a single-institute, single-arm, open-label, Phase II trial, HER2-positive advanced breast cancer patients who had previously received taxanes and trastuzumab were treated with eribulin in combination with pertuzumab and trastuzumab. [Breast] Full Article

Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications

The authors highlight recent studies on the biology of exosomal microRNAs (exo-miRNAs) and discuss potential clinical applications. From a diagnostic perspective, circulating exo-miRNAs may represent breast cancer cell content and/or tumor microenvironmental reactions to cancer cell growth. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Korean IVD Startup NGeneBio Receives CE-IVD Mark for Next Generation Sequencing-Based BRCA I/II Test Panel and Clinical Analysis Software

Molecular diagnostics startup NGeneBio Co., Ltd. has received CE-marking for next generation sequencing-based in vitro diagnostics (IVD) products, BRCAaccuTest™ and clinical analysis software, NGeneAnalySys™ for hereditary breast/ovarian cancer genetic testing. [NGeneBio Co., Ltd. (PR Newswire Association LLC.)] Press Release

Genoptix’s Immuno-Oncology Testing now Covers Additional Tumor Types

Genoptix, Inc. announced that it offers three diagnostic tests that support immunotherapy decisions for solid tumor cancers. [Genoptix, Inc. (PR Newswire Association LLC.)] Press Release

French Scientist Fined for Failure to Disclose Industry Ties

In an unprecedented court case in Paris, an eminent French lung specialist has been fined €50,000 and given a six-month suspended jail sentence because he didn’t disclose his ties to the oil industry during a Senate air-pollution inquiry. [Nature News] Editorial

House Lawmakers Balk at Most Trump Science Cuts in Early Bills

No. That’s the first official answer from lawmakers in the U.S. House of Representatives to President Donald Trump’s request to make deep budget cuts at several key science funding agencies. [ScienceInsider] Editorial

Europe’s Next Big Science-Funding Program Urged to Double Its Budget

Midway through the European Union’s sprawling seven-year, €75-billion research-funding program known as Horizon 2020, scientists are already angling for more money and less red tape in its successor. [Nature News] Editorial

Germany and Poland Launch Research ‘Twinning’ Effort

Germany and Poland are to jointly fund top scientists to start research groups at Polish institutes, in a scheme that could provide a new blueprint for east–west research collaboration in the European Union. [Nature News] Editorial

NEW Developmental Biology and Regeneration
October 25-27, 2017
Stockholm, Sweden

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Positions – Molecular Cancer Research (University of Copenhagen and Rigshospitalet)

NEW Postdoctoral Fellow – Cancer Genomics (University of Texas Health Science Center at Houston)

NEW Canada Research Chair – Tumor Biology (University of Manitoba)

NEW Postdoctoral Research Position – Experimental Oncology (KTH Royal Institute of Technology)

Postdoctoral Positions – Breast Cancer (Northwestern University – Feinberg School of Medicine)

Postdoctoral Training Fellow – Cancer Metabolism (The Francis Crick Institute)

Research Assistant – Breast Cancer (University of British Columbia)

Postdoctoral Training Fellow – Bioinformatics and Cancer Metabolism (The Francis Crick Institute)

Clinician Investigator – Breast Cancer Research (Mayo Clinic)

Postdoctoral Research Associate – Breast Cancer (University of Nebraska Medical Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.